2016 Report Package Includes Two Full Reports Covering Both Aspects of T-cell Immunotherapy of Cancer at a 33% Discount When Purchased Together

Dublin, Sept. 02, 2016 -- Research and Markets has announced the addition of the "Report package: T-Cell Immunotherapy by Bispecific Antibodies and CAR & TCR Engineered T-cells" report to their offering.

The original reports (Linked below) were published in May and August 2016, respectively:

"T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals"

Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR).

Despite stunning clinical results with CD19-targeted CAR T-cells, many major pharmaceutical companies have not embarked on this field of adoptive cell therapy, probably because cell products are a world completely different from that of small molecules or recombinant proteins and antibodies.

Tremendous progress in bispecific antibody technologies during the last decade and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody molecule directed against CD19 lead to an explosion of T-cell redirecting bispecific antibodies in clinical development. Within 18 months, the number of clinical stage T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months.

This report "T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals" as of May 2016 brings you up-to-date information about and analysis of 34 corporate players, 22 key technologies, 47 T-cell and NK-cell redirecting bispecific antibody profiles, business deals and private and public financing rounds.

The report analyzes the pipeline of T-cell and NK-cell redirecting bispecific antibody molecules regarding preferred targets, molecular constructs, dosing schedules, clinical experience, combination study plans, competition with other treatment modalities and the next wave of T-cell and NK-cell redirecting antibodies.

Preferences in bispecific antibody technologies are evaluated regarding drug candidate output, partnering, technological features and impact on clinical administration regimens.

The report highlights the commercial value of T-cell redirecting bispecific antibody immunotherautics in terms of drug prices, sales, company acquisition prices, economic terms of partnering deals, and private or public financing rounds.

All information in the report is fully referenced with 159 scientific references, in many cases with hyperlinks leading to the source of information (abstracts, Posters, papers). Non-scientific references, such as press releases, annual reports or company presentations are disclosed within the text with an embedded hyperlink leading to the online source of information.

What will you find in the report?

- Profiles of 34 companies active in the field;
- Comprehensive description of 23 established and emerging T-cell or NK-cell redirecting antibodies
- Profiles of two approved and 45 T-cell or NK-cell redirecting bispecific antibodies in all phases of development;
- Technology selection and preferences of major pharma;
- Key characteristics of technologies with clinical stage drug candidates
- Emerging alternative bi- and trispecific formats
- Target selection and competition in drug candidates
- Competition of recombinant bispecific molecules with alternative treatment modalities
- Dosing schedules of clinical stage drug candidates based on molecular features
- Economic terms of collaboration and licensing deals;

Who will benefit from the report?

- Venture capital, private equity and investment managers;
- Financial analysts;
- CFO;
- Business development and licensing (BDL) specialists;
- Marketing managers;
- CEO, COO and managing directors;
- Corporate strategy, product and portfolio analysts and managers;
- Chief Technology Officer;
- Cell technology and manufacturing specialists;
- Clinical and preclinical development specialists

"TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016"

The report, "TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs" describes and analyzes the status of the adoptive cell therapy industry as of August 2016.

The report covers autologous and allogeneic engineered chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapy candidates as well as natural killer (NK) cell and CAR engineered NK cells in research and development by biopharmaceutical companies. Cytotoxic lymphocytes (CTLs), donor lymphocyte infusions (TILs) and tumor infiltrating lymphocytes (TILs) complement the spectrum of the report.

The report highlights and discusses

- Company financing;
- Business development & financing;
- Improvements of CAR T-cell therapy incl. gene editing and universal CARTs;
- Engineered TCR T-cells, including TCR target discovery;
- The current status of DLIs, CTLs and TILs;
- Manufacturing of T-cells for adoptive cell therapy;
- NK cells and CAR engineered NK cells;
- International perspective on TCR & CAR T-cell and NK cell therapy; and
- Key success factors & convergence of technologies.

The early and impressive clinical results of anti-CD19 CAR T-cell therapy most probably will see confirmation in ongoing pivotal studies in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) leading to approval as early as 2017.

Supported by Big Pharma money and billions of US$ by private financing rounds, public offerings and partnering money, Novartis, Juno Therapeutics and Kite Pharma are in a close race to be first on market with autologous CD19 CAR T-cell products. Cash-rich Juno and Kite went on a shopping and licensing tour to add numerous technologies like pearls on a string to be prepared for next generation development candidates.

However, clinical experience with CD19 CAR T-cells and other CAR T-cells for hematologic and solid tumors has revealed quite a number of hurdles.

Part of them have to be addressed by protocol issues, such as the pre-conditioning chemotherapy problem, or clinical combination studies with checkpoint inhibitors to modulate the tumor micro-environment. But technological solutions are far more required to improve safety and efficacy as well as convenience and manufacturing of CAR T-cell therapies. Another big issue is the lack of strictly tumor-specific targets.

Among the key technologies are gene editing and TCR target discovery. Companies with such capabilities will have a strong position in financing, partnering and corporate development. This report describes the key players in the field and companies with complementary technologies ideal for joint ventures, or better, mergers.

The analytical evaluation in this report is based on retrieval of information about and detailed description of the profiles of 67 companies and 67 cell therapy product candidates. Information was obtained from 193 scientific references (abstracts, full papers, reviews), press releases, financial information, annual reports, presentations and webcasts. All information sources are fully referenced, either as scientific references or by hyperlinks embedded on the source description for online access to the source.

Who will benefit from this report?

- Technology Officers
- Corporate Development
- Strategic Planning
- Business Development & Licensing
- Corporate Finance
- Portfolio Management
- Investors & Analysts
- Clinical Development
- Research & Development

Companies Featured in Each Report

T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals

- Adimab
- Affimed Therapeutics
- Alligator Biosciences
- Ambrx
- Amgen
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- CytomX
- Eli Lilly
- Emergent BioSolutions
- EngMab
- Eureka Therapeutics
- GEMoaB
- Generon
- Genmab
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- ImmuneXcite
- Immunocore
- Immunomedics
- Janssen Biotech
- MacroGenics
- Merus
- Molecular Partners
- Morphosys
- Neovii Biotech
- OMT Therapeutics
- Pfizer
- Pieris Pharmaceuticals
- Regeneron Pharmaceuticals
- Roche
- Servier
- Wuhan YZY Biopharma
- Xencor
- Zymeworks

TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016

- Adaptimmune
- Adicet Bio
- American Yuva Biomed
- Amgen
- Astellas Pharma
- Atara Biotherapeutics
- Aurora Biopharma
- Autolus
- Beijing Doing Biomedical
- Bellicum Pharmaceuticals
- BioNTech
- BioVec
- Bluebird bio
- CARSgen Therapeutics
- CPT - Cell Processing Therapy & GEMoab Monoclonals
- Catapult Therapy TCR
- Celgene
- Cell Medica
- Cellectis
- CellforCURE
- Cellular Biomedicine Group
- Cellular Therapeutics
- Celyad
- Chimeric Therapeutics
- CytomX Therapeutics
- EUFETS
- Eli Lilly
- Eureka Therapeutics
- Five Prime
- Formula Pharmaceuticals
- Gadeta
- GlaxoSmithKline
- Green Cross LabCell
- iCell Gene Therapeutics
- Immatics US
- Immune Therapeutics
- Innovative Cellular Therapeutics
- Intrexon
- JW Biotechnology
- Janssen
- Juno Therapeutics
- Kite Pharma
- Leucid Bio
- Lion Biotechnologies
- Lonza Wakersville
- MaSTherCell
- MaxCyte
- Medigene
- Merck KGaA
- Miltenyi Biotec
- MolMed
- Mustang Bio
- Nantkwest
- Nextera
- Novartis
- ONO Pharmaceutical Co
- Oxford BioMedica
- Persongen Biomedicine
- Pfizer
- Poseida Therapeutics
- Precision BioSciences
- Progenitor Cell Therapy (PCT)
- Regeneron Pharmaceuticals
- Seattle Genetics
- Servier
- Shanghai GeneChem
- Shenyang Sunshine Pharmaceutical
- Shire (Baxalta)
- Sinbioway Cell Therapy
- Sorrento Therapeutics
- TILT Biotherapeutics
- TNK Therapeutics
- Takara Bio
- The Cell and Gene Therapy Catapult
- Theravectys
- ThermoFisher
- Triumvira Immunologics
- Universal Cells
- Unum Therapeutics
- ViroMed
- Vor Biopharma
- WuXi AppTec
- ZIOPHARM Oncology

For more information about this report visit http://www.researchandmarkets.com/research/ln433l/report_package

Related Topics: Biotechnology, Oncology Drugs

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716